The US Food and Drug Administration (FDA) has accorded its approval for a new Gibralt Occipital Spine System, developed by the US-based Exactech.
The clearance is expected to allow the company to proceed with its plans to make initial launch of the complete Gibralt system in the US market.
The addition of the new device will complete its portfolio of fusion solutions, which according to Exactech, would help clinicians treat the full spine from the occiput, or the back portion of the skull, to the sacrum.
Source: www.orthopedicdevices.medicaldevices-business-review.com; May 7, 2013.
